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Abstract

Clinical trial registration statement: The study is registered at
https://clinicaltrials.gov/ct2/show/NCT01226134?term=itopride
&rank=2. Registration number is NCT01226134.

AIM
To study the effect of itopride on gastric accom
modation, gastric emptying and drinking capacity in
functional dyspepsia (FD).

Informed consent statement: All the subjects included in this
study gave an informed consent before getting recruited for this
study.

METHODS
Randomized controlled trial was conducted to check
the effect of itopride on gastric accommodation, gastric
emptying, capacity of tolerating nutrient liquid and
symptoms of FD. We recruited a total of 31 patients
having FD on the basis of ROME III criteria. After rand
omization, itopride was received by 15 patients while
16 patients received placebo. Gastric accommodation
13
was determined using Gastric Scintigraphy. C labeled
octanoic breadth test was performed to assess gastric
emptying. Capacity of tolerating nutrient liquid drink
was checked using satiety drinking capacity test. The
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Data sharing statement: Technical appendix and dataset
available from corresponding author at shahab.abid@aku.edu.
Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this
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intervention group comprised of 150 mg itopride.
Patients in both arms were followed for 4 wk.

structural, organic or systematic pathology are labeled
[1,2]
as having functional dyspepsia (FD) . Globally pre
valence of FD varies from 1.8% to 57% depending on
[3]
the geographic location and diagnostic criteria used .
There is no published data on community based pre
valence of FD from South Asia but experts consider it
[3,4]
to be an important problem for our population . FD
reduces productivity and incurs a considerable cost on
[5]
health system . Only in 2009 the cost incurred to the
[6]
health system by this morbidity was $18 billion .
Muti-factorial pathogenesis of FD makes it a difficult
[7]
condition to intervene . These patients have inability
of the stomach to change its volume in response to
food, decreased stomach compliance and inability of
[7]
the stomach to empty . Delayed gastric empting is
associated with the symptoms of nausea, vomiting and
[8]
postprandial fullness . These symptoms result in lower
productivity of the patients and a compromised quality
[7,9]
of life . Delayed gastric emptying is found in one third
[8,10]
of the patients with FD
. These patients showed
slower gastric emptying as compare to the normal
[11]
individuals . This is because of sub optimal gastric
[12,13]
myoelectric activities
.
Different drug therapies used for FD that include
eradication of Helicobacter pylori (H. pylori), use of
proton pump inhibitors (PPIs) and anti-depressants
[5,14,15]
failed to demonstrate a convincing effect
. Guide
lines recommend eradication of H. pylori but this
treatment alone depends on the type of the FD being
[15]
treated . Evidence in favor of efficacy for using PPIs
[16]
for all the patients with FD is not clear . It’s argued
that PPIs may only be effective in patients having co[16]
morbid reflux symptoms . Though data suggest that
anti-depressants like mirtazapine might be beneficial for
some sub-groups of FD but still more studies are needed
[17]
to recommend its usage for all patients with FD .
[18]
Symptoms of FD are improved by prokinetic agents .
Metoclopramide can cause extra pyramidal movement
[19]
disorders . Use of domperidone can result in rise in
[20]
prolactin level leading to gynaecomastia . Cisapride
[21]
can result in prolonged QT interval and arrhythmias .
Itopride is a dopamine (D2) antagonist with peripheral
action. It doesn’t cause severe elevation of prolactin
and or pathological changes on electrocardiogram
[22]
(ECG) . A recent meta-analysis concluded that itopride
improves the symptoms of early satiety and postprandial
[23]
fullness . Through this study we wanted to find the
effect of itopride on gastric accommodation, gastric
emptying and capacity of tolerating nutrient liquid drink
in patients with FD in Pakistani population.

RESULTS
Mean age of the recruited participant 33 years (SD
= 7.6) and most of the recruited individuals, i.e. , 21
(67.7%) were males. We found that there was no effect
of itopride on gastric accommodation as measured at
different in volumes in the itopride and control group
with the empty stomach (P = 0.14), at 20 min (P =
0.38), 30 min (P = 0.30), 40 min (P = 0.43), 50 min
(P = 0.50), 60 min (P = 0.81), 90 min (P = 0.25) and
120 min (P = 0.67). Gastric emptying done on a sub
sample (n = 11) showed no significant difference (P =
0.58) between itopride and placebo group. There was
no significant improvement in the capacity to tolerate
liquid in the itopride group as compared to placebo (P =
0.51). Similarly there was no significant improvement of
symptoms as assessed through a composite symptom
score (P = 0.74). The change in QT interval in itopride
group was not significantly different from placebo (0.10).
CONCLUSION
Our study found no effect of itopride on gastric accommo
dation, gastric emptying and maximum tolerated volume
in patients with FD.
Key words: Itopride; Gastric emptying; Gastric accom
modation; Functional dyspepsia; Dyspepsia
© The Author(s) 2017. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Through this study we wanted to find the
effect of itopride on gastric accommodation, gastric
emptying and drinking capacity in patients with
functional dyspepsia (FD) in Pakistani population.
The strength of our study was that we used objective
13
measures, i.e. , gastric scintigraphy and C labeled
octanoic acid breath test to measure gastric accom
modation and gastric emptying. Diagnosis of FD was
based on ROME III criteria and was done after using
extensive investigations to rule out organic cause
for the symptoms. We found no effect of itopride on
gastric accommodation, gastric emptying and maximum
tolerated volume in patients with FD in our study.
Abid S, Jafri W, Zaman MU, Bilal R, Awan S, Abbas A. Itopride
for gastric volume, gastric emptying and drinking capacity in
functional dyspepsia. World J Gastrointest Pharmacol Ther
2017; 8(1): 74-80 Available from: URL: http://www.wjgnet.
com/2150-5349/full/v8/i1/74.htm DOI: http://dx.doi.org/10.4292/
wjgpt.v8.i1.74

MATERIALS AND METHODS
We conducted a randomized controlled trial to see the
effect of itopride on gastric emptying. This study was
conducted after approval from Aga Khan University
Ethical Review Committee (Clinical trial registration
number: NCT01226134). Subject for this study were

INTRODUCTION
Patients presenting with epigastric pain and burning,
early satiation and postprandial fullness without any
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enrolled after written informed consent that was made
on the basis of declaration of Helsinki.

Breath sample was taken before test meal (150 mL of
13
water with a sandwich of scrambled egg containing C
octanoic acid and 250 mL of orange juice) and at an
interval of every 15 min for 4 h and then half-hourly for
another two hours. During the measurement time the
subject remained sedentary while reading or watching
television. If necessary limited movements between the
breaths collections were permitted.

Study population

Total of 31 patients were recruited for the purpose of
this study from the gastroenterology clinics of Aga Khan
University Hospital. Eligibility criteria used for recruiting
these patients was; age equal to or greater than 18
years, diagnosed as FD on the base of Rome III criteria,
negative for H. pylori on gastric biopsy and Urea Breath
Test, negative duodenal biopsy for giardiasis or celiac
disease or any other established organic pathology,
and normal upper abdominal ultrasound. We excluded;
pregnant women, patients taking other medications
that alter gastric motility like macrolide and anti-emetics
and antibiotics.

Satiety drinking capacity test: Subjects after an
overnight fast were told to come at 8:30 AM in the
morning. They were asked to grade their satiety from 0
to 5 (5 being the maximum satiety). A drink containing
6.5 g fat/100 mL, 1.1 g carbohydrate and 5 g of protein
(nutridrink kcl 150/100 mL) which tasted of vanilla was
taken by the participants at room temperature. Subjects
drank at the rate of 15 mL/min. Symptoms were scored
at every five minutes interval. Test was ceased once a
[27]
score of 5 is achieved .

Randomization

Before undergoing randomization patients were asse
ssed for symptoms that included epigastric discom
fort, heart burn, acid regurgitation, upper abdominal
pain, belching, nausea, early satiety, and postprandial
fullness. Blood samples of these patients were taken
to check for serum hemoglobin level, white blood cell
count, platelet count, serum alanine aminotransferese
(SGPT) and prolactin level. Electrocardiogram of the
patient was performed to find out the QT interval at
the baseline. Single photon emission tomography
and satiety drinking test was performed to measure
gastric accommodation at baseline. After completing
the baseline investigations, out of all patients that were
recruited 15 were randomly allocated to the intervention
group while 16 were randomly allocated to the placebo
group. Patients in the intervention group received 150
mg of itopride for 4 wk. Patients were instructed to take
antacids as and when required.

Symptoms of FD: Dyspeptic symptoms which included
epigastric pain, epigastric discomfort, heart burn, acid
regurgitation, upper abdominal pain, belching, nausea,
early satiety and postprandial fullness were assessed
at baseline and at 4 wk with validated 7-point global
[28]
overall symptom scale .

Sample size calculation

Change in gastric volumes between baseline and post
prandial (accommodation) was the primary endpoint for
this study. To detect 16% difference in the Itopride and
placebo with power of 80% and 5% level of significance
a sample size of 15 subjects was needed in each group.
This effect size of 16% [100 × (difference in group
means divided by overall mean of the two groups)]
corresponds to the difference in the two groups that
was relevant clinically. The Analysis of coefficient of
variance (ANCOVA) was done for this analysis.

Outcome measures

Gastric accommodation: Gastric accommodation was
determined by estimating the change in gastric volumes
using Gastric Scintigraphy and by the help of computer
software which convert the gastric images into 3D
[24]
images and calculate the estimated gastric volumes .
Gastric volumes were determined before giving itopride
or placebo agent and after completion of intervention
period. We injected 99mTc pertechnetate followed
by the use of Analyze software for reconstruction of
tomographic images. These images were acquired after
an overnight fast among all the participants and then
after giving 300 mL of nutrient drink at an interval of
20, 30, 40, 50, 60, 90 and 120 min. Analyze PC 2.5
software system was used to find out stomach volume
[24]
measurements .

Statistical analysis

For the purpose of this study, mean and standard devia
tion were reported for quantitative variables. Means and
standard errors adjusted for covariates were reported
using ANCOVA. The difference in the change in volume
between itporide and the placebo group was compared
using Man Whitney U test.

RESULTS
A total of thirty-one individuals were recruited for the
purpose of this study. Mean age of these individuals was
33 years. Most of the recruited individuals, 21 (67.7%)
were males. After randomization into Itopride and
placebo groups, the groups were similar on variables
like age, gender, serum haemoglobin, white blood cells,
platelet count, serum creatinine, SGPT, prolactin level
and QT interval on ECG (Table 1). There was no lost to
follow up.

13

Gastric emptying: After an overnight fast, C labeled
octanoic breadth test was performed to assess gastric
[25,26]
emptying
. A test meal containing 13C was given to
patient which is supposed to be completed in 10 min.
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Table 1 Distribution of age and gender by intervention arm

200

Variable

Itopride

95%CI change in volume (endline - baseline)

n = 31

P value

Placebo

Age mean (SD)
34.2 (6.4)
31.9 (8.5)
Gender n (%)
Male
10 (66.7)
11 (68.8)
Female
5 (33.3)
5 (31.3)
Hb (g/dL) mean (SD)
13.6 (2.3)
14.1 (1.7)
WBC (× 10 Eq/L) mean (SD)
8.1 (2.0)
7.7 (1.9)
Platelet count (× 10 Eq/L) mean (SD) 257.3 (59.5) 250.5 (57.2)
Creatinine (mg/mL) median (IQR)
0.9 (0.5)
0.8 (0.3)
SGPT (IU/L) median (IQR)
20 (9.0)
25.5 (17.0)
Prolactin level (mg/mL) (IQR)
7.3 (3.6)
5.7 (2.7)
QT interval mean (SD)
394.1 (21.6) 399.2 (22.9)

0.40
1.001
0.50
0.52
0.75
0.05
0.09
0.29
0.53

0

-200
Arm
Intervention
Placebo

-400

1

Fischer Exact test. WBC: White blood cell; IQR: Interquartile range.

Itopride

Placebo

-22.2 (± 15.4)
-201.7 (± 102.4)
0.14 (± 22.8)
-27.6 (± 32.2)
-60.0 (± 31.2)
-3.1 (± 36.5)
3.8 (± 29.8)
16.7 (± 28.9)
0.4 (± 0.4)

7.5 (± 14.9)
-31.5 (± 99.1)
-36.4 (± 22.1)
-37.4 (± 31.2)
-3.0 (± 30.2)
15.0 (± 35.4)
-31.8 (± 28.8)
23.3 (± 28.0)
0.2 (± 0.4)

22.5 (± 18.1)
-5.8 (1.0)

36.0 (17.5)
-4.7 (0.9)

0

m

in

in
m

12

90

m

in

in
m

60

in

50

in

m

m

Figure 1 Schintigraphy.

2

P = 0.58

1

0

-1

-2
Itopride

Gastric accommodation

Gastric accommodation was checked using gastric
scintigraphy by computing the change in gastric volume
at empty stomach, 20, 30, 40, 50, 60, 90 and 120
min. We found that there was no statistically significant
difference in the itopride and placebo group on gastric
accommodation as measured with the difference in
volume in the itopride and control group with the
empty stomach (P = 0.14), at 20 min (P = 0.38), 30
min (P = 0.30), 40 min (P = 0.43), 50 min (P =0.50),
60 min (P = 0.81), 90 min (P = 0.25) and 120 min (P
= 0.67) (Figure 1). Mean volumes to measure gastric
accommodation by scintigraphy using ANCOVA adjusted
for age and gender were computed (Table 2).

Intervention

Placebo

Figure 2 Breadth test.

there was no significant improvement in the capacity
to tolerate liquid in the itopride group as compared to
placebo (P = 0.51) (Figure 3).

Symptoms of FD

There was no significant improvement of symptoms
as assessed through a composite symptom score (P =
0.74) in the intervention group as compared to placebo
(Figure 4). Similarly we didn’t find any significant
improvement in the individual symptoms that included
epigastric pain (P = 0.83), epigastric discomfort (P =
0.22), heart burn (P = 0.74), upper abdominal pain (P
= 0.51), nausea (P = 0.08), early satiety (P = 0.34)
and postprandial fullness (P = 0.25) (Table 3).
The change in QT interval as a result of itopride
group was not statistically different from placebo (0.10).
Similarly itopride didn’t alter the serum prolactin level
in the intervention group as compare to the placebo
group.

Gastric emptying

Gastric emptying was done by doing breath tests
on a sub sample (n = 11). There was no statistically
significant difference (P = 0.58) between intervention
and control group in gastric emptying (Figure 2).

Capacity of tolerating liquid drink

At the end of the intervention (Itopride or placebo)
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Time

95%CI change in volume (endline - baseline)

Mean (± SE)
Change in volume (post-pre) using
scintigraphy
Fasting
20 min
30 min
40 min
50 min
60 min
90 min
120 min
Effect on gastric emptying on 13C
labeled octanoic acid breath test
(post-pre)
Effect on drinking capacity (post-pre)
Change in Symptom score (post-pre)

Fa
s

Table 2 Mean volumes to measure gastric accommodation by
scintigraphy using ANCOVA adjusted for age and gender
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Table 3 Median Symptom score along with interquartile range at baseline and end of four weeks (placebo vs itopride) n = 31
Symptoms

Baseline

Epigastric pain
Epigastric discomfort
Heart burn
Upper abdominal pain
Belching
Nausea
Early satiety
Postprandial Fullness
Total Symptom score

End of four weeks

Itopride

Placebo

P value

Itopride

Placebo

P value

3.0 (1.0)
2.0 (1.0)
1.0 (3.0)
3.0 (2.0)
1.0 (1.0)
2.0 (1.0)
2.0 (2.0)
2.0 (3.0)
19.0 (9.0)

4.0 (2.0)
1.0 (1.0)
1.0 (1.8)
1.5 (2.5)
1.0 (0.0)
1.0 (0.0)
2.0 (3.0)
2.0 (2.8)
16.5 (5.0)

0.18
0.03
0.37
0.32
0.10
0.04
0.56
0.82
0.41

2.0 (1.0)
1.0 (1.0)
1.0 (1.0)
2.0 (1.0)
1.0 (1.0)
1.0 (1.0)
1.0 (1.0)
1.0 (1.0)
12.0 (3.0)

2.0 (1.0)
1.0 (1.0)
1.0 (1.0)
1.5 (1.0)
1.0 (0.0)
1.0 (0.0)
1.0 (0.0)
1.0 (1.0)
11.5 (4.5)

0.83
0.22
0.74
0.51
0.02
0.08
0.34
0.25
0.71

-3.00

P = 0.51
95%CI change in symptom score
(endline - baseline)

95%CI change in drinkng capacity
(endline - baseline)

80.00

60.00

40.00

20.00

0.00

P = 0.74

-4.00
-5.00
-6.00
-7.00
-8.00
-9.00

-20.00
Itopride

Intervention

Placebo

Itopride

Intervention

Placebo

Figure 3 Drinking capacity.

Figure 4 Change in Symptom score by intervention group.

DISCUSSION

that itopride improves symptoms related to FD but we
found that it is not true for our set of patients. Itopride
failed to show improvement in the overall symptom
score as well as effect on individual symptoms including
early satiety and postprandial fullness as opposed to
[23]
the conclusion of a recent meta-analysis . Through
previous studies we know that to achieve a considerable
improvement in the symptoms of one patient, we need
[32]
to treat six patients of FD . Itopride was efficacious in
reducing the symptom score in Chinese patients having
[33]
FD . Small sample size might be the reason which
resulted in our inability to detect an improvement in
individual symptoms as a result of itopride usage as
compared to placebo. Our sample included younger
individuals and therefore could not study the effect of
itopride in older patients with FD. Lack of variability in
the age might have affected the results.
Itopride is advocated for the treatment of FD as it
is safer drug as compare to other prokinetic agents. In
our study we found that itopride didn’t prolong the QT
interval compared to placebo. Similarly itopride did not
raise the prolactin level compared placebo. Therefore
we can say that though itopride did not demonstrate
any effect it is safer prokinetic.
Inability of itopride to effect gastric accommodation
and gastric emptying might be because of the genetic
variability in the dopamine-D2 receptor subtype. TaqIA

In this study we tested the effect of itopride on some
of the pathophysiological mechanisms attributed to
the causation of symptoms in FD patients. Impaired
accommodation is implied as one of the important
factors considered to be associated with symptoms
in FD patients. A primary objective of our study was
to check whether itopride has any effect on gastric
accommodation. We didn’t find any effect of itopride on
gastric accommodation when assessed through gastric
scintigraphy as compared to placebo. This finding is in
disagreement with a similar study which showed that
[29]
itopride worsens the gastric accommodation .
We also found that itopride didn’t effect gastric emp
13
tying as assessed through C labeled octanoic acid
breath test. A study done in Japan showed that itopride
[30]
improves gastric emptying among dyspeptic patients .
On the other hand a cross over study that was also
done in Japan showed that itopride does not improve
[31]
gastric emptying . Our study also found that itopride
did not improve the drinking capacity as assessed
through satiety drinking capacity test as compare to the
placebo. This finding is in line with the similar findings in
another study where it was found that itopride failed to
[29]
improve the nutrient drink test induced symptoms .
Though in previous studies it was demonstrated
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polymorphism is one example where dopamine-D2
receptor is not fully expressed resulting in compromised
[34]
functionality of this receptor . Mechanistic studies can
identify the genetic factors like dopamine-D2 receptor
variability which are anticipated to effect the efficacy of
itopride among FD patients in our setting.
The strength of our study was that we used objec
13
tive measures, i.e., gastric scintigraphy and C labeled
octanoic acid breath test to measure gastric accom
modation and gastric emptying. Diagnosis of FD was
based on ROME III criteria and was done after using
extensive investigations to rule out organic cause for
the symptoms. The study was conducted at one center
and therefore we couldn’t capture a broad spectrum
of patients suffering from FD. We only checked the
effect of 150 mg of itopride on gastric functions and
symptoms. We didn’t use an objective measure to find
out the absorbed amount of drug in the body.
We found no effect of itopride on gastric accom
modation, gastric emptying and maximum tolerated
volume in patients with FD in our study.

2
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